Charles Schwab’s Achieve Life Sciences ACHV Stock Holding History

Charles Schwab’s Portfolio ACHV Stock Details ACHV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.52M	Buy	232,138 +189,138	+440%	+$902K	﹤0.01%	2876
2026 Q1	$126K	Buy	43,000 +23,000	+115%	+$102K	﹤0.01%	3354
2025 Q4	$99.4K	Buy	+20,000	New	+$87.2K	﹤0.01%	3397
2025 Q2	–	Sell	-89,562	Closed	-$239K	–	3496
2025 Q1	$239K	Hold	89,562	–	–	﹤0.01%	3236
2024 Q4	$315K	Hold	89,562	–	–	﹤0.01%	3262
2024 Q3	$425K	Sell	89,562 -6,324	-7%	-$28.9K	﹤0.01%	3201
2024 Q2	$451K	Buy	+95,886	New	+$462K	﹤0.01%	3242
2022 Q2	–	Sell	-10,306	Closed	-$79K	–	3538
2022 Q1	$79K	Buy	+10,306	New	+$76.7K	﹤0.01%	3455
2014 Q2	–	Sell	-9	Closed	-$230K	–	3089
2014 Q1	$230K	Hold	9	–	–	﹤0.01%	2906
2013 Q4	$163K	Hold	9	–	–	﹤0.01%	2998
2013 Q3	$179K	Hold	9	–	–	﹤0.01%	2953
2013 Q2	$190K	Buy	+9	New	+$201K	﹤0.01%	2921

Other funds holding ACHV

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Charles Schwab's ACHV Position: Q2 2026 in Review

Charles Schwab increased its Achieve Life Sciences (ACHV) stake by 440% in Q2 2026, buying an estimated $902K and bringing the position to 232,138 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2876.

Charles Schwab first reported a position in ACHV in Q2 2013 and has held it in 12 quarters since. 111 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

Charles Schwab held 232,138 shares of Achieve Life Sciences worth $1.52M as of Q2 2026.
Charles Schwab bought 189,138 Achieve Life Sciences shares in Q2 2026, an estimated $902K.
Achieve Life Sciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2876 holding.
Charles Schwab first reported a position in Achieve Life Sciences in Q2 2013 and has held it in 12 quarters since.
111 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.